- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14:06 | Oncoinvent ASA: Oncoinvent to Present at TD Cowen 45th Annual Health Care Conference | 158 | Business Wire | Oncoinvent ASA, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced that management will present at the TD Cowen 45th Annual Health Care Conference... ► Artikel lesen | |
| Do | Oncoinvent ASA: Invitation to Result Presentation Q4 2024 | 313 | PR Newswire | OSLO, Norway, Feb. 20, 2025 /PRNewswire/ -- In connection with the release of the results for the full year and fourth quarter 2024, Oncoinvent invites to the following events:
Thursday... ► Artikel lesen | |
| 19.02. | Oncoinvent ASA to present at various conferences | - | Oslo Børs | ||
| 18.02. | Oncoinvent ASA: Registration of new share capital | - | Oslo Børs | ||
| 06.02. | Oncoinvent ASA: Last day of the subscription period in the subsequent offering | 1 | Oslo Børs | ||
| 04.02. | Oncoinvent ASA: Grant of share options - mandatory notification of trade | - | Oslo Børs | ||
| 23.01. | Oncoinvent ASA: Commencement of subscription period for subsequent offering | 2 | Oslo Børs | ||
| 22.01. | Oncoinvent ASA: Resolution to increase the share capital in connection with subsequent offering | - | Oslo Børs | ||
| ONCOINVENT Aktie jetzt für 0€ handeln | |||||
| 22.01. | Oncoinvent ASA: Key information relating to subsequent offering | - | Oslo Børs | ||
| 10.01. | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA 10.01.2025 | 489 | Xetra Newsboard | The following instruments on XETRA do have their first trading 10.01.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 10.01.2025
Aktien
1 ES06445809T5 Iberdrola S.A. BZR
2... ► Artikel lesen | |
| 18.12.24 | Oncoinvent ASA: Financial calendar | 2 | Oslo Børs | ||
| 13.12.24 | Oncoinvent lists on Euronext Growth Oslo | 3 | Euronext | ||
| 13.12.24 | Oncoinvent ASA: First day of trading on Euronext Growth Oslo and publication of information document | 3 | Oslo Børs | ||
| 12.12.24 | Oncoinvent ASA: Notifiable transactions in connection with Private Placement | 1 | Oslo Børs | ||
| 05.12.24 | Oncoinvent ASA announces oversubscribed private placement | 350 | PR Newswire | OSLO, Norway, Dec. 5, 2024 /PRNewswire/ -- Oncoinvent ASA ('Oncoinvent' or the 'Company') is pleased to announce that it has today successfully completed the bookbuilding process for a private... ► Artikel lesen | |
| 04.12.24 | Oncoinvent ASA: Oncoinvent Announces Agreement with ARTBIO to Collaborate on Radiopharma Laboratory Facilities | 268 | Business Wire | Oncoinvent ASA, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced that it has entered into an agreement with ARTBIO, a clinical-stage radiopharmaceutical... ► Artikel lesen | |
| 11.11.24 | Oncoinvent ASA: Oncoinvent Announces Promising Interim Results for Radspherin as a Potential Treatment for Peritoneal Carcinomatoses | 326 | Business Wire | Oncoinvent ASA, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced an interim data readout of the Phase 1/2a studies of Radspherin® for the... ► Artikel lesen | |
| 01.11.24 | Oncoinvent Announces Publication of 18-Month Safety and Efficacy Data from the Phase 1/2a Study of Radspherin in Colorectal Cancer | 339 | Business Wire | Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced the publication of data from the Phase 1/2a study of Radspherin® in colorectal... ► Artikel lesen | |
| 28.10.24 | Oncoinvent AS: Oncoinvent to Present at JonesTrading Virtual Radiopharma Day | 222 | Business Wire | Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced that members of management will participate in a virtual panel discussion... ► Artikel lesen | |
| 10.10.24 | Oncoinvent Announces First Patient Dosed in its Phase 2 Clinical Trial of Radspherin in Ovarian Cancer Patients | 262 | Business Wire | U.S. Food and Drug Administration (FDA) recently granted Fast Track designation for Radspherin® for the treatment of patients with peritoneal metastases from ovarian cancer
Oncoinvent, a clinical... ► Artikel lesen |
Seite:
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TEMPUS AI | 62,26 | +5,40 % | Tempus AI Aktie: Langfristige Planung vorgestellt | Der Technologiekonzern Tempus AI verzeichnet derzeit bemerkenswerte Bewegungen im Aktienhandel, wobei mehrere hochrangige Führungskräfte in der vergangenen Woche umfangreiche Aktienverkäufe tätigten.... ► Artikel lesen | |
| EVOTEC | 8,250 | -0,42 % | Evotec Aktie: Steht das Schlimmste noch bevor? | Die Evotec-Aktie verzeichnete am Mittwoch einen spürbaren Rückschlag an der Börse. Im XETRA-Handel musste das Biotechnologieunternehmen einen Kursverlust von 4,2 Prozent hinnehmen, wodurch der Aktienkurs... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 8,340 | +2,52 % | Spotlight on Recursion Pharmaceuticals: Analyzing the Surge in Options Activity | ||
| ARCUTIS BIOTHERAPEUTICS | 13,220 | +8,18 % | Arcutis rises as lead product undergoes FDA review for label expansion | ||
| QIAGEN | 37,695 | +0,05 % | ANALYSE-FLASH: Berenberg senkt Ziel für Qiagen auf 48 Euro - 'Buy' | HAMBURG (dpa-AFX Broker) - Die Privatbank Berenberg hat das Kursziel für Qiagen von 54,90 auf 48,00 Euro gesenkt und die Einstufung auf "Buy" belassen. Das vierte Quartal sei solide gewesen, auch wenn... ► Artikel lesen | |
| BIONTECH | 108,40 | +2,55 % | BioNTech-Aktie: Geht's jetzt wieder hoch? | Es ist still geworden um die BioNTech-Aktie. Sie kommt seit drei Monaten nicht vom Fleck und notiert aktuell bei 119,58 US$. Ist das die Ruhe vor dem nächsten Sturm? Übernahme abgeschlossen Die letzte... ► Artikel lesen | |
| ENVERIC BIOSCIENCES | 2,290 | +87,70 % | Pre-market Movers: Enveric Biosciences, Interactive Strength, Flywire, Grocery Outlet Holding, National Vision Holdings | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.50 A.M. ET).In the Green Enveric Biosciences, Inc. (ENVB) is up over 155%... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 42,370 | +4,03 % | MoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update | Initiated the Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (HS) and the Phase 3 IZAR program in patients with active psoriatic arthritis... ► Artikel lesen | |
| ONCO-INNOVATIONS | 1,790 | -3,76 % | EQS-Media: Onco-Innovations Ltd.: Vielversprechender Wachstumsimpuls? Onco-Tochter Inka Health meldet provisorische USPTO-Patentanmeldung für SynoGraph | EQS-Media / 22.02.2025 / 13:05 CET/CEST
Onco-Innovations Ltd. (ISIN: CA68237C1059 / WKN: A3EKSZ), Onco oder das Unternehmen, freut sich bekannt zu geben, dass seine hundertprozentige Tochtergesellschaft... ► Artikel lesen | |
| BEAM THERAPEUTICS | 27,890 | -6,53 % | Beam Therapeutics Inc. Q4 Earnings Summary | WASHINGTON (dpa-AFX) - Below are the earnings highlights for Beam Therapeutics Inc. (BEAM):Earnings: -$90.35 million in Q4 vs. $142.80 million in the same period last year.
EPS: -$1.09 in... ► Artikel lesen | |
| DAY ONE BIOPHARMACEUTICALS | 9,840 | -16,75 % | Day One Biopharmaceuticals stock target cut to $36 at H.C. Wainwright | ||
| TARSUS PHARMACEUTICALS | 42,630 | +3,16 % | Tarsus stock holds Buy rating and $73 target at H.C. Wainwright | ||
| SPRINGWORKS THERAPEUTICS | 54,23 | +0,44 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates | - Achieved $61.5 million and $172.0 million in fourth quarter and full year 2024 OGSIVEO® (nirogacestat) U.S. net product revenues, respectively - - Received FDA approval of GOMEKLI (mirdametinib)... ► Artikel lesen | |
| ARCELLX | 60,28 | -3,89 % | Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights | REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 18,280 | +1,05 % | Akeso, Inc.: Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer's ADCs | HONG KONG, Feb. 24, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that its partner on ivonescimab, Summit Therapeutics... ► Artikel lesen |
Das Unternehmen ONCOINVENT ASA kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,155 Euro und damit -6,28 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ONCOINVENT ASA finden Sie auf Wallstreet Online.
